Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Thursday, Sep 07, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The APHINITY trial showed that adding pertuzumab to chemotherapy and trastuzumab (Herceptin) statistically improved disease-free survival, but the difference was small.

Tolaney says that the patients who benefit significantly from pertuzumab are those who have node-positive hormone receptor-negative disease.
 
SELECTED
LANGUAGE


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The APHINITY trial showed that adding pertuzumab to chemotherapy and trastuzumab (Herceptin) statistically improved disease-free survival, but the difference was small.

Tolaney says that the patients who benefit significantly from pertuzumab are those who have node-positive hormone receptor-negative disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x